FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 358 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 How to Get Started With Exercising at Home During Cancer July 7, 2022 Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are... September 30, 2019 Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... November 10, 2021 Load more HOT NEWS 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... NCI and CRUK Take on Cancer’s Toughest Problems
